Cargando…

Patient Perception of Route of Rectal Administration of Live Biotherapeutic Product for Recurrent Clostridioides difficile Infection

INTRODUCTION: CDI is a recurrent disease that is treated with antibiotics, but patients commonly experience repeat infections with significant impacts on hospital budgets and patient health quality. Standard of care management includes the antibiotics, vancomycin and fidaxomicin, which frequently pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feuerstadt, Paul, Oneto, Caterina, Tillotson, Glenn, Van Hise, Nicholas W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475298/ https://www.ncbi.nlm.nih.gov/pubmed/37667688 http://dx.doi.org/10.2147/PPA.S415681

Ejemplares similares

Microbiota-Based Live Biotherapeutic RBX2660 for the Reduction of Recurrent Clostridioides difficile Infection in Older Adults With Underlying Comorbidities
por: Tillotson, Glenn, et al.
Publicado: (2022)

Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
por: Orenstein, Robert, et al.
Publicado: (2023)

Clostridioides difficile infection: microbe-microbe interactions and live biotherapeutics
por: Wang, Ruojun
Publicado: (2023)

Perception of quality of life in people experiencing or having experienced a Clostridioides difficile infection: a US population survey
por: Lurienne, Lise, et al.
Publicado: (2020)

706. An Ad Hoc Subgroup Analysis of a Phase 3, Open-Label Study Indicates Efficacy and Safety of Fecal Microbiota, Live-jslm in Participants With Recurrent Clostridioides difficile Infection and Renal Impairment
por: Fischer, Monika, et al.
Publicado: (2023)

236. Treatment of Recurrent Clostridioides difficile Infection With RBX2660 in Patients ≥ 65 Years Old With Underlying Comorbidities
por: Tillotson, Glenn S, et al.
Publicado: (2022)

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
por: Garey, Kevin W, et al.
Publicado: (2023)

The development of live biotherapeutics against Clostridioides difficile infection towards reconstituting gut microbiota
por: Zhang, Yongrong, et al.
Publicado: (2022)

Treating Clostridioides difficile: Could Microbiota-based Live Biotherapeutic Products Provide the Answer?
por: Nagarakanti, Sandhya, et al.
Publicado: (2023)

Human Fecal Bile Acid Analysis after Investigational Microbiota-Based Live Biotherapeutic Delivery for Recurrent Clostridioides difficile Infection
por: Papazyan, Romeo, et al.
Publicado: (2023)

129. Antimicrobial Resistance Genes Were Reduced Following Administration of Investigational Microbiota-Based Live Biotherapeutic RBX2660 to Individuals with Recurrent Clostridioides difficile Infection
por: Hau, Heidi, et al.
Publicado: (2021)

Effect of Fecal Microbiota, Live-Jslm (REBYOTA [RBL]) on Health-Related Quality of Life in Patients With Recurrent Clostridioides difficile Infection: Results From the PUNCH CD3 Clinical Trial
por: Garey, Kevin W, et al.
Publicado: (2023)

Gut microbiota and microbiota-based therapies for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Transitions of care in Clostridioides difficile infection: a need of the hour
por: Khanna, Sahil, et al.
Publicado: (2022)

366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Evolution of clinical guidelines for antimicrobial management of Clostridioides difficile infection
por: Chaar, Abdelkader, et al.
Publicado: (2021)

Role of the microbiome in essential metabolism in the human gut and its implications for Clostridioides difficile infection
por: Chopra, Teena, et al.
Publicado: (2023)

Clinical burden of recurrent Clostridioides difficile infection in the medicare population: A real-world claims analysis
por: Feuerstadt, Paul, et al.
Publicado: (2022)

Heterogeneity of Randomized Controlled Trials of Fecal Microbiota Transplantation in Recurrent Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2021)

522. Significant Improvement in Health-Related Quality of Life (HRQL) with RBX2660: Results from a Phase 3 Randomized, Placebo-Controlled Trial in Recurrent Clostridioides Difficile Infection (PUNCH CD3)
por: Feuerstadt, Paul, et al.
Publicado: (2022)

1042. Safety of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Braun, Tricia, et al.
Publicado: (2021)

167. Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Individuals with Recurrent Clostridioides difficile Infection: Data from Five Prospective Clinical Studies
por: Bancke, Lindy, et al.
Publicado: (2021)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo
por: Murphy, Christopher K, et al.
Publicado: (2023)

Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
por: Reveles, Kelly R., et al.
Publicado: (2023)

Clinical complications in patients with primary and recurrent Clostridioides difficile infection: A real-world data analysis
por: Feuerstadt, Paul, et al.
Publicado: (2021)

RBX7455, a Non-frozen, Orally Administered Investigational Live Biotherapeutic, Is Safe, Effective, and Shifts Patients’ Microbiomes in a Phase 1 Study for Recurrent Clostridioides difficile Infections
por: Khanna, Sahil, et al.
Publicado: (2020)

Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota–Based Therapeutic
por: Berenson, Charles S, et al.
Publicado: (2023)

Health care resource utilization and costs of recurrent Clostridioides difficile infection in the elderly: a real-world claims analysis
por: Nelson, Winnie W, et al.
Publicado: (2021)

The Importance of a Broad Consortium of Bacteria for a Healthy Gastrointestinal tract: A Narrative Review of the Live Biotherapeutic Product REBYOTA
por: Tillotson, Glenn, et al.
Publicado: (2023)

19. The Impact of Investigational Purified Microbiome Therapeutic SER-109 on Health-Related Quality of Life (HRQoL) of Patients with Recurrent Clostridioides difficile Infection (rCDI) in ECOSPOR III, a Placebo-Controlled Clinical Trial
por: Hohmann, Elizabeth, et al.
Publicado: (2021)

1064. Treatment Success in Reducing Recurrent Clostridioides difficile Infection with Investigational Live Biotherapeutic RBX2660 Is Associated with Microbiota Restoration: Consistent Evidence from a Phase 3 Clinical Trial
por: Blount, Ken, et al.
Publicado: (2021)

The burden of Clostridioides difficile infection in COVID-19 patients: A systematic review and meta-analysis
por: Granata, Guido, et al.
Publicado: (2022)

Assessment of Quality of Life Among Patients With Recurrent Clostridioides difficile Infection Treated with Investigational Oral Microbiome Therapeutic SER-109: Secondary Analysis of a Randomized Clinical Trial
por: Garey, Kevin W., et al.
Publicado: (2023)

Clostridioides difficile in COVID-19 Patients, Detroit, Michigan, USA, March–April 2020
por: Sandhu, Avnish, et al.
Publicado: (2020)

Gut metabolites predict Clostridioides difficile recurrence
por: Dawkins, Jennifer J., et al.
Publicado: (2022)

Clostridium difficile--a moving target
por: Tillotson, Glenn S., et al.
Publicado: (2011)

Retrospective Analysis of the Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA(TM)) Administered Under Enforcement Discretion to Patients With Clostridioides difficile Infection
por: Feuerstadt, Paul, et al.
Publicado: (2023)

Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial
por: Sims, Matthew D., et al.
Publicado: (2023)

Risk Factors Associated with Recurrent Clostridioides difficile Infection
por: Negrut, Nicoleta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g9rn5smlee0ugotc0fh2o0t7pp